hCD3EDG/hEpCAM

Nomenclature

C57BL/6Smoc-Cd3etm1(hCD3E)Cd3dtm1(hCD3D)Cd3gtm1(hCD3G)Epcamtm1(hEPCAM)Smoc

Cat. NO.

NM-HU-220123

Strain State

Repository Live

Export PDF

Model Description

hCD3EDG(NM-HU-220120) mice were crossed with hEpCAM(NM-HU-210032) mice to generate hCD3EDG/hEpCAM mice.

Validation Data

Table.1 Blood routine examination in male hCD3EDG/hEpCAM mice.

image.png

Table.2 Blood routine examination in female hCD3EDG/hEpCAM mice.

image.png


image.png

Fig.1 Detection of lymphcytes population in the (A) peripheral blood and (B) spleen of 8-week-old male and female homozygous hCD3EDG/hEpCAM dKI mice by FACS (n=3). 

image.png

Fig.2 Pathological analysis of 8-week-old female hCD3EDG/hEpCAM dKI mice by H＆E staining. 

There were no obvious pathological changes in these tissues.

image.png

Fig.3 Pathological analysis of 8-week-old male hCD3EDG/hEpCAM dKI mice by H＆E staining. 

There were no obvious pathological changes in these tissues.

image.png

Fig.4 Detection of mouse EpCAM expression in 8-week-old wild-type mice (WT) by IHC with an anti-mouse EpCAM antibody. 

The arrows indicate the positive mouse EpCAM staining (brown) in each tissue. (40x Magnification) 

image.png

Fig.5 Detection of human EpCAM expression in 8-week-old wild-type mice (WT) and homozygous hCD3EDG/hEpCAM knockin mice by IHC with an anti-human EpCAM antibody. 

The arrows indicate the positive EpCAM staining (brown) in each tissue. The results show that human EpCAM is highly expressed in the intestine and kidney of hCD3EDG/hEpCAM knockin mice. (40x Magnification)  

You may also like

Shanghai Model Organisms Center Inc has licensed CRISPR-Cas9 technology from Broad Institute

On Dec 16, 2018, Broad Institute and Shanghai Model Organisms Center Inc (SMOC) has entered into a non-exclusive license agreement under which Broad has granted SMOC worldwide rights to commercialize a service platform for genetically modified mouse models under Broad's intellectual property.

Learn more
Workshop：Progress and Advances in Preclinical immuno-Oncology Research

SMOC’s Annual Progress and Advances in Preclinical immuno-Oncology Research: The workshop is designed as a forum for ideas and opinions exchange on how to decrease the rate of clinical failures in oncology and immuno-oncology.

Learn more